HIKMA PHARMS PLC S/ADR - HKMPY STOCK NEWS

Hikma Pharmaceuticals participated in a naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day. The event, held at Groves High School in Savannah, Georgia, marks Hikma's milestone of donating over 600,000 doses of naloxone in the past three years. Hikma is working with government officials and the White House Office of National Drug Control Policy to expand access to naloxone, a vital tool for reversing overdoses.

Hikma manufactures multiple forms of naloxone, including generic injectable vials, prefilled syringes, and KLOXXADO® (naloxone 8mg) intranasal spray. The company's Hikma Community Health initiative partners with frontline organizations to expand naloxone access through donations, partnerships, and awareness programs. Hikma also provides a Co-Pay Assistance Program for KLOXXADO® to increase accessibility and reduce out-of-pocket costs.

Hikma Pharmaceuticals PLC announces the shelf-life extension of KLOXXADO® (naloxone HCl) nasal spray 8mg from 24 to 36 months. This change applies to products manufactured from March 2024 onwards. KLOXXADO® contains twice the naloxone dose of Narcan® Nasal Spray 4mg, offering a important treatment option for opioid overdose reversal.

The extended shelf-life is particularly beneficial for frontline responders and individuals carrying KLOXXADO® for emergency use. This development comes as organizations like the CDC and American Medical Association note that higher doses of naloxone may be necessary to counteract poisoning from illicit fentanyl and other synthetic opioids. Hikma emphasizes its role in combating the opioid crisis, especially as International Overdose Awareness Day approaches on August 31st.

Hikma Pharmaceuticals collaborates with the Office of National Drug Control Policy to combat the opioid overdose epidemic in the US, focusing on expanding access to naloxone. The company welcomed Dr. Rahul Gupta to its Columbus facility for discussions and a tour regarding the production of overdose reversal medicine.

Hikma Pharmaceuticals PLC announces the launch of COMBOGESIC IV, an opioid-free pain relief medicine in the US. The medicine is a combination of acetaminophen and ibuprofen approved by the US FDA for adult pain management. It provides superior analgesia efficacy and shorter onset to analgesia compared to individual drugs. The Phase 3 clinical trial showed more than double pain relief compared to individual drugs, making it a promising alternative for hospitals and healthcare providers.

Activ Surgical completes its first international surgery at Abdali Hospital in Jordan using its ActivSight technology, which provides enhanced visualization and real-time surgical insights. Dr. Mohamad Rassoul Abu-Nuwar, trained at the Esophageal Institute - West Penn Hospital, performed a surgical bariatric revision procedure using ActivPerfusion Mode. Hikma Ventures, a lead investor, supports the global expansion of ActivSight.

Guardant Health, Inc. (Nasdaq: GH) and Hikma Pharmaceuticals PLC announced a partnership to promote Guardant Health’s cancer screening and monitoring tests in the Middle East and North Africa. The agreement aims to improve access to next-generation sequencing tests in the region, where cancer cases are estimated to double by 2040.

Guardant Health, a leading precision oncology company (Nasdaq: GH), partners with Hikma Pharmaceuticals PLC to promote its cancer screening and tumor mutation profiling tests in the Middle East and North Africa. The agreement provides Hikma with exclusive rights to commercialize Guardant Health's products in the majority of countries in the MENA region. This partnership aims to improve access to next-generation sequencing tests in a region where cancer cases are estimated to double by 2040.

Hikma Pharmaceuticals announces donation of over 375,000 doses of KLOXXADO® to combat opioid overdose epidemic

Hikma Pharmaceuticals and Glenmark Specialty announced the US launch of RYALTRIS™, a nasal spray for treating seasonal allergic rhinitis (SAR), approved by the FDA for patients aged 12 and older. This combination therapy relieves nasal and ocular symptoms, offering onset relief in 15 minutes. With 60 million Americans affected by allergic rhinitis, this product addresses a significant unmet need, particularly as many patients report inadequate symptom control. Hikma aims to expand its specialty business in the US through this launch, utilizing its existing salesforce to reach healthcare providers.